Irinotecan in second-line chemotherapy for advanced gastric cancer in the application of.docVIP

 PAGE \* MERGEFORMAT 4 Irinotecan in second-line chemotherapy for advanced gastric cancer in the application of Author: Wang Feng, Li Mei-Qian Li Mao Guo Rise and Fall of the new [Abstract] Objective: To evaluate irinotecan (CPT-11) in second-line chemotherapy for advanced gastric cancer in the clinical efficacy and toxicity. Methods: Of the 25 cases of advanced gastric cancer patients with CPT-11 combined with fluorouracil (5-FU) / Leucovorin (LV) or cisplatin (DDP) second-line chemotherapy. Specific programs: CPT-11 150 mg/m2 infusion, d1; LV 200 mg/m2 infusion, d1-2; 5-FU400 mg/m2 bolus d1-2; 600 mg/m2 continuous infusion 22 h, d1-2, or CPT-11 150 mg/m2 infusion, d1; DDP40 mg/m2 infusion, d1, are 14 days in a cycle. 3 cycles (6 weeks) were evaluated. Results: Complete remission (CR) 0 patients and partial remission (PR) 6 cases of stable (SD) 8 cases of progress (PD) 11 patients, the total effective rate was 24%, disease control rate of 56%, median time to tumor progression (TTP) 3.8 months and median survival of 7.5 months. The most common adverse events were alopecia, neutropenia, diarrhea and nausea and vomiting, Ⅲ / Ⅳ degree rates were 40%, 32%, 4% and 16%. Conclusion: CPT-11-based joint program safe and effective second-line treatment of advanced gastric cancer, adverse reactions could be tolerated and can be controlled. [Keywords:] gastric cancer; irinotecan; fluorouracil; Leucovorin; cis-platinum; chemical treatment Gastric cancer is a common one in China, the annual incidence of about 40 million deaths of about 30 million [1]. Chemotherapy is the main treatment of advanced gastric cancer, most of the first-line chemotherapy in advanced gastric cancer patients shortly after the progress of disease appears. So search for a safe and effective second-line chemotherapy in the treatment of advanced gastric cancer has important clinical significance. I Bureau since November 2005 ~ December 2007 Application of irinotecan (CPT-11) based combination in t